title: Transcriptionally targeted in vivo gene therapy for carcinoembrionic antigen-producing adenocarcinoma.
abstract: Inoperable adenocarcinoma in colon or lung shows resistance to conventional anti-cancer therapy. For these cancers, the feasibility of transcriptionally targeted killing of carcinoembryonic antigen (CEA)-producing adenocarcinoma cells was investigated. Adenovirus vectors carrying a CEA promoter to express E. coli lacZ (AdCEALacZ) or herpes simplex thymidine kinase (AdCEATK) were made and their in vitro and in vivo tumoricidal effects on CEA-producing or non-producing colon and lung cancer cells were evaluated. In vitro infection with AdCEALacZ showed significantly higher CEA promoter-driven lacZ expression in CEA-producing adenocarcinoma cells including VMRC-LCD and LoVo than in CEA-non-producing cells. AdCEATK-infected LoVo showed higher sensitivity to ganciclovir than control vector-infected LoVo or AdCEATK-infected HeLa both in vitro and in subcutaneously implanted tumors of nude mice. Moreover, total tumor elimination in vivo was achieved by either pre-infection of as few as 30% of cells comprising tumors or by direct in vivo injection of AdCEATK to pre-established LoVo tumors. In addition, CEA promoter-driven lacZ expression in LoVo cells was enhanced by the addition of interleukin-6 (IL-6) in vitro. These results provide a rationale for CEA-promoter-driven, adenovirus-mediated gene therapy for CEA-producing adenocarcinomas in colon and lung with reduced toxicity to normal cells.
authors.affiliation: Second Department of Internal Medicine, Hiroshima University School of Medicine, Japan.
authors.forename: F
authors.initials: F
authors.lastname: Konishi
authors.forename: H
authors.initials: H
authors.lastname: Maeda
authors.forename: Y
authors.initials: Y
authors.lastname: Yamanishi
authors.forename: K
authors.initials: K
authors.lastname: Hiyama
authors.forename: S
authors.initials: S
authors.lastname: Ishioka
authors.forename: M
authors.initials: M
authors.lastname: Yamakido
mesh_terms: D000230:Adenocarcinoma / Q000276:immunology* / Q000628:therapy*; D000256:Adenoviridae / Q000235:genetics; D000818:Animals; D001483:Base Sequence; D002272:Carcinoembryonic Antigen / Q000096:biosynthesis* / Q000235:genetics; D003110:Colonic Neoplasms / Q000276:immunology / Q000628:therapy; D017931:DNA Primers / Q000235:genetics; D005260:Female; D015316:Genetic Therapy; D005822:Genetic Vectors; D006801:Humans; D015850:Interleukin-6 / Q000627:therapeutic use; D007763:Lac Operon; D008175:Lung Neoplasms / Q000276:immunology / Q000628:therapy; D051379:Mice; D008819:Mice, Nude; D011401:Promoter Regions, Genetic
chemical_list: D002272:Carcinoembryonic Antigen; D017931:DNA Primers; D015850:Interleukin-6